Page last updated: 2024-12-10

leukotriene e4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Leukotriene E4: A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

leukotriene E4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID5280879
CHEMBL ID509456
CHEBI ID15650
SCHEMBL ID11263165
MeSH IDM0027182

Synonyms (45)

Synonym
gtpl3352
(5s-(5r*,6s*(s*),7e,9e,11z,14z))-6-((2-amino-2-carboxyethyl)thio)-5-hydroxy-7,9,11,14-eicosatetraenoic acid
s-{(1r,2e,4e,6z,9z)-1-[(1s)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl}-l-cysteine
(5s,6r,7e,9e,11z,14z)-6-(l-cystein-s-yl)-5-hydroxyicosa-7,9,11,14-tetraenoic acid
CHEBI:15650 ,
5s-hydroxy,6r-(s-cysteinyl),7e,9e,11z,14z-eicosatetraenoic acid
BSPBIO_001370
LMFA03020002
(7e,9e,11z,14z)-(5s,6r)-6-(cystein-s-yl)-5-hydroxyicosa-7,9,11,14-tetraenoate
C05952
leukotriene e4
lte4
75715-89-8
(7e,9e,11z,14z)-(5s,6r)-6-(cystein-s-yl)-5-hydroxyeicosa-7,9,11,14-tetraenoate
NCGC00163400-01
NCGC00163400-02
7,9,11,14-eicosatetraenoic acid, 6-((2-amino-2-carboxyethyl)thio)-5-hydroxy-, (5s-(5r*,6s*(s*),7e,9e,11z,14z))-
leukotriene e
leukotrien e4
CHEMBL509456 ,
bdbm50297387
(5s,6r,7e,9e,11z,14z)-6-[(2r)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
8eyt8atl7g ,
unii-8eyt8atl7g
7,9,11,14-eicosatetraenoicacid, 6-[[(2r)-2-amino-2-carboxyethyl]thio]-5-hydroxy-, (5s,6r,7e,9e,11z,14z)-
[3h]lte4
gtpl5863
(5s,6r,7e,9e,11z,14z)-6-(2-amino-2-carboxyethyl)sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
leukotriene e4 [mi]
lte-4
SCHEMBL11263165
5s-hydroxy-6r-(s-cysteinyl)-7e,9e,11z,14z-eicosatetraenoic acid
HMS3402E12
[5s-[5r*,6s*(s*),7e,9e,11z,14z]]- 6-[(2-amino-2-carboxyethyl)thio]-5-hydroxy-7,9,11,14-eicosatetraenoic acid
[5s-[5r*,6s*(s*),7e,9e,11z,14z]]- 6-[(2-amino-2-carboxyethyl)thio]-5-hydroxy-7,9,11,14-eicosatetraenoate
DTXSID20897510
(5s,6r,7e,9e,11z,14z)-6-[(2r)-2-amino-2-carboxyethyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
Q2705859
(5s,6r,7e,9e,11z,14z)-6-(((r)-2-amino-2-carboxyethyl)thio)-5-hydroxyicosa-7,9,11,14-tetraenoic acid
leukotriene e4 lipid maps(r) ms standard
CS-0061845
HY-113465
STARBLD0009611
PD119335
AKOS040758330

Research Excerpts

Overview

Leukotriene E4 (LTE4) is a major leukotRIene metabolite in urine.

ExcerptReferenceRelevance
"Leukotriene E4 (LTE4) is a major leukotriene metabolite in urine. "( Immunofiltration purification for urinary leukotriene E4 quantitation.
Sloan, S; Wenzel, SE; Westcott, JY, 1997
)
2

Toxicity

ExcerptReferenceRelevance
" At least 2 weeks after completion of the study, all patients received on an open basis 25 mg rofecoxib without any adverse effects."( Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
Bochenek, G; Mejza, F; Nagraba, K; Nizankowska, E; Swierczynska, M; Szczeklik, A, 2001
)
0.31
" Cyclooxygenase 2 inhibitors are a safe alternative in patients with AERD."( Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.
Bartra, J; Muñoz-Cano, R; Picado, C; Roca, J; Sánchez-López, J; Serrano, C; Valero, A, 2011
)
0.37
"The drug was well tolerated by all patients, with no adverse reactions."( Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.
Bartra, J; Muñoz-Cano, R; Picado, C; Roca, J; Sánchez-López, J; Serrano, C; Valero, A, 2011
)
0.37
"There was no clear difference in adverse events between placebo and active drug-treated subjects in either study."( Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Ambery, C; Bain, G; Bentley, J; Evans, JF; Hutchinson, JH; King, CD; Norris, V; Rewolinski, M; Santini, AM; Schaab, K; Stock, N; van de Wetering de Rooij, J; Yamada, M; Zunic, J, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic and pharmacodynamic properties of a novel 2-indolealkanoic acid derivative (MK-0591), a potent inhibitor of leukotriene biosynthesis, were investigated in healthy male Japanese volunteers."( Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.
Friedman, BS; Hara, K; Kanamaru, M; Kosuge, K; Nakashima, M; Takenaga, N; Tanaka, W; Uchiyama, N; Uematsu, T, 1995
)
0.29
" After multiple-dose administration (50-1,000 mg once daily for 11 days), there were no significant differences in the pharmacokinetic parameters between the first and last days of treatment."( Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).
Arruda, JM; Bain, G; Evans, JF; Hutchinson, JH; King, CD; Li, Y; Lorrain, DS; Milne, GL; Moran, M; Prasit, P; Rewolinski, M; Roffel, AF; Santini, AM; Schaab, K; Schuilenga-Hut, P; Shapiro, D; van de Wetering de Rooij, S, 2010
)
0.36
" Blood samples were collected for GSK2190915 concentrations and blood and urine were collected to measure leukotriene B₄ and leukotriene E₄, respectively, as pharmacodynamic markers of drug activity."( Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Ambery, C; Bain, G; Bentley, J; Evans, JF; Hutchinson, JH; King, CD; Norris, V; Rewolinski, M; Santini, AM; Schaab, K; Stock, N; van de Wetering de Rooij, J; Yamada, M; Zunic, J, 2013
)
0.39
" Maximum plasma concentrations of GSK2190915 and area under the curve increased in a dose-related manner and mean half-life values ranged from 16-34 h."( Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Ambery, C; Bain, G; Bentley, J; Evans, JF; Hutchinson, JH; King, CD; Norris, V; Rewolinski, M; Santini, AM; Schaab, K; Stock, N; van de Wetering de Rooij, J; Yamada, M; Zunic, J, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" In man, high oral bioavailability was indicated."( Pharmacokinetics and metabolism of a leukotriene D4/E4-antagonist (2-[3'-(2"-quinolylmethoxy)phenylamino]benzoic acid) in rat, dog,guinea pig and man.
Ahnfelt-Rønne, I; Christensen, A; Eilertsen, E; Kissmeyer, AM; Rastrup-Andersen, N, 1990
)
0.28
" These results suggest that blood may play a role in regulating the bioavailability of cysteinyl-containing LTs which could be of relevance to their excretion in man."( The biotransformation in vitro of cysteinyl leukotrienes in blood of normal and asthmatic subjects.
Barnes, NC; Costello, JF; Evans, JM; Piper, PJ; Sampson, AP; Zakrzewski, JT, 1989
)
0.28
" Such measurements, combined with bioavailability data from other species, may be useful for predicting biochemical activity in man."( Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
Black, C; Brideau, C; Chan, C; Ford-Hutchinson, A; Frenette, R; Tagari, P, 1993
)
0.29
" The absolute bioavailability of 5q has been found to be 28% in the rat, as compared to 68% for ICI 204,219, with significant levels of 5q observed in the blood of rats up to 24 h postdose."( Substituted 3-(phenylmethyl)-1H-indole-5-carboxamides and 1-(phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes.
Aharony, D; Brown, FJ; Buckner, CK; Cronk, LA; Jacobs, RT; Kirkland, KM; Kusner, EJ; Neilson, KL, 1993
)
0.29
"Representative nonsteroidal anti-inflammatory drug (NSAID) cyclooxygenase inhibitors such as ibuprofen, naproxen, and indomethacin were used as orally bioavailable scaffolds to design selective 5-lipoxygenase (5-LO) inhibitors."( Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
Bell, RL; Bouska, J; Brooks, CD; Carter, GW; Dellaria, JF; Hulkower, KI; Kolasa, T; Rodriques, KE; Summers, JB, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" The dose of agonist that produced a 35% fall in specific airways conductance (PD35 SGaw) was obtained by linear interpolation from the logarithmic dose-response curve."( Effect of indomethacin on leukotriene4-induced histamine hyperresponsiveness in asthmatic subjects.
Christie, PE; Hawksworth, R; Lee, TH; Spur, BW, 1992
)
0.28
" Airway responsiveness to each agonist was determined by the cumulative dose of agonist required to induce a 35% fall in specific airway conductance (PD35) as determined by linear interpolation of the log dose-response curve."( The effect of inhalation of the leukotriene receptor antagonist, SK&F 104353, on leukotriene C4- and leukotriene E4-induced bronchoconstriction in subjects with asthma.
Christie, PE; Lee, TH; Spur, BW, 1991
)
0.5
" L-Serine borate (45 mM), an inhibitor of gamma-glutamyl transpeptidase, shifted the dose-response curve of LTC4 to the left by 161-fold, and L-cysteine (6 mM), an inhibitor of aminopeptidase, shifted the dose-response curves of LTC4 and LTD4 to the left by 67- and 23-fold, respectively."( Characterization of sulfidopeptide leukotriene responses in sheep tracheal smooth muscle in vitro.
Abraham, WM; Jackowski, JT; Tomioka, K, 1991
)
0.28
" SK&F S-106203 produced dose-dependent rightward shifts in the LTC4 and LTE4 dose-response curves."( SK&F S-106203 inhibits leukotriene C4, leukotriene D4 and leukotriene E4 vasopressor responses in the conscious rat.
Eckardt, RD; Egan, JW; Newton, JF; Slivjak, MJ; Smith, EF, 1990
)
0.52
" Airways responsiveness to each bronchoconstrictor agonist was assessed by constructing cumulative dose-response curves, and the dose that produced a 35% decrease in specific airways conductance (PD35) was obtained by linear interpolation."( Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine.
Arm, JP; Crea, AE; Fong, CY; Hawksworth, RJ; Lee, TH; O'Hickey, SP; Spur, BW, 1990
)
0.28
" Complete dose-response curves were first generated to LTC4, LTD4 and LTE4: those agents produced dose-dependent increases in arterial blood pressure, with ED20 values (i."( ICI 198615 is an antagonist of leukotriene C4, leukotriene D4 and leukotriene E4 vasopressor responses in the conscious rat.
Slivjak, MJ; Smith, EF, 1990
)
0.52
" SK&F 104353 produced dose-dependent, parallel shifts to the right in the LTC4 dose-response curve."( Antagonism of leukotriene C4, leukotriene D4 and leukotriene E4 vasoconstrictor responses in the conscious rat with the peptidoleukotriene receptor antagonist SK&F 104353: evidence for leukotriene D4 receptor heterogeneity.
Eckardt, RD; Newton, JF; Slivjak, MJ; Smith, EF, 1989
)
0.53
" An estimated 1-2 pg of LY170680 delivered to the airways by nebuliser 1 hour beforehand, produced a 6 fold lateral displacement to the right of the dose-response curve to LTD4."( The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig.
Bond, A; Boot, JR; Gooderham, R; O'Brien, A; Parsons, M; Thomas, KH, 1989
)
0.28
" During the initial 15-min period, comparison of the dose-response curves revealed that histamine produced a much larger increase in extravascular albumin content than any of the leukotrienes."( Time-dependent differences in the vasopermeability response to intradermal peptidoleukotrienes.
Gary, RK; Hawley, SB; Nieves, AL; Spada, CS; Woodward, DF,
)
0.13
" The dose-response curve was bimodal for LTC4 with two maxima at 10(-8) and 10(-16) M (X2."( Leukotrienes C4 and D4 stimulate the release of luteinizing hormone-releasing hormone from rat median eminence in vitro.
Dray, F; Gerozissis, K; Saadi, M, 1987
)
0.27
" L-Serine borate complex, 45 mM, used as an inhibitor of the degradation of LTC4 to LTD4 by the enzyme gamma-glutamyl transpeptidase, in paired airway segments (adjacent segments from the same branch), produced a small degree (about 3-fold) of shift to the right of the dose-response curve and reduction of the maximum response to LTC4."( Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4.
Bernstein, PR; Buckner, CK; Coursin, DB; Krell, RD; Laravuso, RB; Will, JA, 1986
)
0.27
" A dose-response curve (0."( Differential effects of leukotrienes C4, D4, and E4 in the pulmonary and systemic vasculature of sheep.
Ahmed, T; Marchette, B; Wanner, A; Wasserman, M; Yerger, L,
)
0.13
" Allergen inhalation challenge was performed four hours after dosing and FEV1 was measured for eight hours."( Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses.
Arm, JP; Bell, GS; Hawksworth, RJ; Lee, TH; MacMillan, R; Nasser, SM; Spruce, KE; Williams, AJ, 1994
)
0.29
" A single dose of aspirin was administered four hours after dosing and FEV1 was measured for six hours."( Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.
Arm, JP; Bell, GS; Foster, S; Lee, TH; MacMillan, R; Nasser, SM; Spruce, KE; Williams, AJ, 1994
)
0.29
" Although its ability to inhibit the cyclooxygenase pathway was readily observed in whole blood and in vivo, tenidap's 5-LO blockade could not be demonstrated by ionophore stimulated human blood, nor after oral dosing in rat models in which peritoneal leukotriene products were measured after challenge with three different stimuli."( Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty, TJ; Cheng, JD; Ernest, MJ; Eskra, JD; Griffiths, RJ; Joseph, PA; Kadin, SB; Loose, LD; Moore, PF; Murase, S; Nagahisa, A; Pazoles, PP; Pillar, JS; Sweeney, FJ, 1997
)
0.3
"5) concentrations were logged, suggesting a nonlinear dose-response relationship between particulate matter exposure concentrations and airway mediators of asthma, for which the relationship tends to flatten at higher concentrations."( The response of children with asthma to ambient particulate is modified by tobacco smoke exposure.
Gelfand, EW; Rabinovitch, N; Silveira, L; Strand, M, 2011
)
0.37
" This negative interaction, the smaller effect of particulate matter exposure in children exposed to higher ETS, may be related to a nonlinear dose-response relationship between asthma mediators and particulate exposures."( The response of children with asthma to ambient particulate is modified by tobacco smoke exposure.
Gelfand, EW; Rabinovitch, N; Silveira, L; Strand, M, 2011
)
0.37
"To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor, GSK2190915, after oral dosing in two independent phase I studies, one in Western European and one in Japanese subjects, utilizing different formulations."( Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Ambery, C; Bain, G; Bentley, J; Evans, JF; Hutchinson, JH; King, CD; Norris, V; Rewolinski, M; Santini, AM; Schaab, K; Stock, N; van de Wetering de Rooij, J; Yamada, M; Zunic, J, 2013
)
0.39
"GSK2190915 is well-tolerated with pharmacokinetics and pharmacodynamics in Western European and Japanese subjects that support once daily dosing for 24 h inhibition of leukotrienes."( Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Ambery, C; Bain, G; Bentley, J; Evans, JF; Hutchinson, JH; King, CD; Norris, V; Rewolinski, M; Santini, AM; Schaab, K; Stock, N; van de Wetering de Rooij, J; Yamada, M; Zunic, J, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
leukotrieneAny icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated.
amino dicarboxylic acid
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
L-cysteine thioetherAny L-cysteine derivative obtained by conversion of the thiol group into a sulfide.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (21)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Leukotrienes (LT) and Eoxins (EX)1329
Disease1278231
Infectious disease89579
Eicosanoid metabolism via lipooxygenases (LOX)040
Leishmania infection6626
Leishmania parasite growth and survival2018
Anti-inflammatory response favouring Leishmania parasite infection2018
LTC4-CYSLTR mediated IL4 production57
Prostaglandin and leukotriene metabolism in senescence619
Leukotriene metabolic pathway219
Arachidonic acid (AA, ARA) oxylipin metabolism076
Parasitic Infection Pathways6626
Folic acid network070
Eicosanoid metabolism via lipoxygenases (LOX)040
Selenium micronutrient network095
Eicosanoid synthesis026
Arachidonic acid metabolism via LOX (Lipooxygenase) pathway033

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)9.83002.62005.97679.8300AID681600
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2Y purinoceptor 12Homo sapiens (human)EC50 (µMol)0.00130.00130.00130.0013AID431380
Cysteinyl leukotriene receptor 2Homo sapiens (human)EC50 (µMol)0.29300.00440.10210.2930AID1877362
Cysteinyl leukotriene receptor 1Homo sapiens (human)EC50 (µMol)0.10400.00090.05500.1040AID1877361
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
monoatomic ion transportP2Y purinoceptor 12Homo sapiens (human)
substrate-dependent cell migration, cell extensionP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
hemostasisP2Y purinoceptor 12Homo sapiens (human)
calcium-mediated signalingP2Y purinoceptor 12Homo sapiens (human)
cerebral cortex radial glia-guided migrationP2Y purinoceptor 12Homo sapiens (human)
cell projection organizationP2Y purinoceptor 12Homo sapiens (human)
lamellipodium assemblyP2Y purinoceptor 12Homo sapiens (human)
platelet activationP2Y purinoceptor 12Homo sapiens (human)
positive regulation of integrin activation by cell surface receptor linked signal transductionP2Y purinoceptor 12Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
positive regulation of monoatomic ion transportP2Y purinoceptor 12Homo sapiens (human)
response to axon injuryP2Y purinoceptor 12Homo sapiens (human)
regulation of chemotaxisP2Y purinoceptor 12Homo sapiens (human)
positive regulation of chemotaxisP2Y purinoceptor 12Homo sapiens (human)
establishment of localization in cellP2Y purinoceptor 12Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionP2Y purinoceptor 12Homo sapiens (human)
platelet aggregationP2Y purinoceptor 12Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 12Homo sapiens (human)
visual system developmentP2Y purinoceptor 12Homo sapiens (human)
positive regulation of ruffle assemblyP2Y purinoceptor 12Homo sapiens (human)
regulation of microglial cell migrationP2Y purinoceptor 12Homo sapiens (human)
positive regulation of microglial cell migrationP2Y purinoceptor 12Homo sapiens (human)
immune responseCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
inflammatory response to antigenic stimulusCysteinyl leukotriene receptor 1Homo sapiens (human)
calcium ion transportCysteinyl leukotriene receptor 1Homo sapiens (human)
chemotaxisCysteinyl leukotriene receptor 1Homo sapiens (human)
defense responseCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationCysteinyl leukotriene receptor 1Homo sapiens (human)
respiratory gaseous exchange by respiratory systemCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of angiogenesisCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionCysteinyl leukotriene receptor 1Homo sapiens (human)
establishment of localization in cellCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of glial cell proliferationCysteinyl leukotriene receptor 1Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cellular response to hypoxiaCysteinyl leukotriene receptor 1Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 12Homo sapiens (human)
guanyl-nucleotide exchange factor activityP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 12Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
protein bindingCysteinyl leukotriene receptor 2Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneP2Y purinoceptor 12Homo sapiens (human)
cell surfaceP2Y purinoceptor 12Homo sapiens (human)
membraneP2Y purinoceptor 12Homo sapiens (human)
cell projection membraneP2Y purinoceptor 12Homo sapiens (human)
cell body membraneP2Y purinoceptor 12Homo sapiens (human)
cellular_componentCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID370722Activity at MRP1 in human HeLa T5 cells assessed as ATP-dependent drug transport at 50 nM measured per mg of protein2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1).
AID1617043Stability in human HepG2 cells at 0.52 uM up to 4 hrs by LC-MS/MS analysis
AID1617044Stability in human HepG2 cells at 2.6 uM up to 4 hrs by LC-MS/MS analysis
AID681342TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of biological chemistry, Jun-11, Volume: 274, Issue:24
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.
AID678989TP_TRANSPORTER: uptake in liver plasma membrane vesicles of Wistar rat1990The Journal of biological chemistry, Nov-05, Volume: 265, Issue:31
ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates.
AID1617046Drug excretion in healthy human urine by LC-MS/MS analysis
AID681351TP_TRANSPORTER: uptake in membrane vesicle from MRP1-expressing HeLa cells1996Cancer research, Mar-01, Volume: 56, Issue:5
Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump.
AID431380Agonist activity at human P2Y12 receptor2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).
AID1877361Agonist activity at human CysLT1 receptor2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1.
AID1877362Agonist activity at human CysLT2 receptor2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1.
AID681600TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells2001Molecular pharmacology, May, Volume: 59, Issue:5
Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2.
AID1346857Mouse GPR17 (Class A Orphans)2008PloS one, , Volume: 3, Issue:10
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2000Biochemical and biophysical research communications, Aug-02, Volume: 274, Issue:2
The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor.
AID1346073Human CysLT2 receptor (Leukotriene receptors)1998Molecular pharmacology, Apr, Volume: 53, Issue:4
Identification and characterization of two cysteinyl-leukotriene high affinity binding sites with receptor characteristics in human lung parenchyma.
AID1346031Human CysLT1 receptor (Leukotriene receptors)1999Nature, Jun-24, Volume: 399, Issue:6738
Characterization of the human cysteinyl leukotriene CysLT1 receptor.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2011Molecular pharmacology, Feb, Volume: 79, Issue:2
Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2011Molecular pharmacology, Feb, Volume: 79, Issue:2
Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2000Biochemical and biophysical research communications, Aug-02, Volume: 274, Issue:2
The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor.
AID1346031Human CysLT1 receptor (Leukotriene receptors)1998Molecular pharmacology, Apr, Volume: 53, Issue:4
Identification and characterization of two cysteinyl-leukotriene high affinity binding sites with receptor characteristics in human lung parenchyma.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2000Molecular pharmacology, Dec, Volume: 58, Issue:6
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2000Molecular pharmacology, Dec, Volume: 58, Issue:6
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.
AID1346031Human CysLT1 receptor (Leukotriene receptors)1999Molecular pharmacology, Sep, Volume: 56, Issue:3
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2000The Journal of biological chemistry, Sep-29, Volume: 275, Issue:39
Characterization of the human cysteinyl leukotriene 2 receptor.
AID1345419Mouse oxoglutarate receptor (Oxoglutarate receptor)2013The Journal of biological chemistry, Apr-19, Volume: 288, Issue:16
Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (946)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990287 (30.34)18.7374
1990's316 (33.40)18.2507
2000's200 (21.14)29.6817
2010's117 (12.37)24.3611
2020's26 (2.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.23 (24.57)
Research Supply Index7.01 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index51.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials118 (11.97%)5.53%
Reviews63 (6.39%)6.00%
Case Studies11 (1.12%)4.05%
Observational2 (0.20%)0.25%
Other792 (80.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]